Trial reportHaematologica2018
A phase II/III randomized, multicenter trial of prednisone/sirolimus
Open access · goldAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIComparative Study
In one paragraph
Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.Stem cell reviews and reports · 2026Pooled it
- Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study.Bone marrow transplantation · 2024Trial
- Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study.International journal of molecular sciences · 2024Trial
- Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.Blood advances · 2022Trial
- Trial
- ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Chronic graft-<I>versus</i>-host disease in the era of posttransplant cyclophosphamide.Haematologica · 2026Article
- Cyclosporine in hematological disorders: mechanisms, clinical practice and emerging advances.Annals of hematology · 2026Review
- [Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Chronic Graft-versus-host Disease, Part 2: Clinical Success and Roadmap to the Future.Transplantation · 2025Review
- A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned.British journal of haematology · 2025Article
- Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease.Immunotherapy · 2025Review
- Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.Blood advances · 2025Article
- Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease.Advances in experimental medicine and biology · 2025Review
- mTOR inhibitors potentially preserve fertility in female patients with haematopoietic malignancies: a narrative review.Annals of hematology · 2024Review
- Sirolimus as add-on therapy to corticosteroids for moderate-severe chronic graft versus host disease.Blood cell therapy · 2024Article
- Review
- [Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.Journal of the American Academy of Dermatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 15 institutions in 1 country.
Paul A CarpenterFred Hutchinson Cancer Research Center, Seattle, WA pcarpent@fredhutch.org.
Brent R LoganMedical College of Wisconsin, Milwaukee, WI.
Stephanie J LeeFred Hutchinson Cancer Research Center, Seattle, WA.
Daniel J WeisdorfUniversity of Minnesota, Minneapolis, MN.
Laura JohnstonStanford Hospital and Clinics, Stanford, CA.
Luciano J CostaUniversity of Alabama at Birmingham, AL.
Carrie L KitkoVanderbilt University School of Medicine, Nashville, TN.
Javier Bolaños-MeadeSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Stefanie SarantopoulosDuke University Medical Center, Durham, NC.
Amin M AlousiUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Sunil AbhyankarThe University of Kansas Medical Center, Kansas City, KS.
Edmund K WallerEmory University School of Medicine, Atlanta, GA.
Adam MendizabalThe Emmes Corporation, Rockville, MD.
Jiaxi ZhuThe Emmes Corporation, Rockville, MD.
Kelly A O'BrienThe Emmes Corporation, Rockville, MD.
Aleksandr LazaryanUniversity of Minnesota, Minneapolis, MN.
Juan WuThe Emmes Corporation, Rockville, MD.
Eneida R NemecekOregon Health and Sciences University, Portland, OR.
Steven Z PavleticExperimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD.
Corey S CutlerDana Farber Cancer Institute, Boston, MA, USA.
Mary M HorowitzMedical College of Wisconsin, Milwaukee, WI.
Mukta AroraUniversity of Minnesota, Minneapolis, MN.
BMT CTN.
Emmes (United States) · USUniversity of Minnesota · USFred Hutch Cancer Center · USMedical College of Wisconsin · USDana-Farber Cancer Institute · USDuke Medical Center · USEmory University · USNational Cancer Institute · USOregon Health & Science University · USSidney Kimmel Comprehensive Cancer Center · USStanford Health Care · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alabama at Birmingham · USUniversity of Kansas Medical Center · USVanderbilt University · US
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MTUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos, Robert S Negrin · 1989 to 2026
$73.3MBlood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MTUMOR VACCINESP01CA015396 · NCI · JOHNS HOPKINS UNIVERSITY · PI JONES, RICHARD J · 1985 to 2016
$38.1MNIH Chronic GVHD Study GroupZIABC011743 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLETIC, STEVEN · 2016 to 2025
$10.2MPathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHDR01HL129061 · NHLBI · DUKE UNIVERSITY · PI Stefanie Sarantopoulos · 2015 to 2026
$7.7MBMT CTN Core - Fred Hutchinson Cancer CenterUG1HL069246 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 2017 to 2026
$2.2MCity of Hope Core Clinical Center for the Blood and Marrow Transplant Clinical Trials NetworkUG1HL069278 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI RYOTARO NAKAMURA · 2017 to 2026
$2.2MBMT CTN Core - Dana-Farber Cancer Institute and MGH ConsortiumUG1HL069249 · NHLBI · DANA-FARBER CANCER INST · PI Mahasweta Gooptu · 2017 to 2026
$2.2MBMT CTN Core - University of MinnesotaUG1HL069290 · NHLBI · UNIVERSITY OF MINNESOTA · PI Mark Juckett, Margaret L MacMillan · 2017 to 2026
$1.9MBMT Core - Stanford UniversityUG1HL069291 · NHLBI · STANFORD UNIVERSITY · PI Lori Muffly · 2017 to 2026
$1.7MNCI NIH HHS P01 CA015396NCI NIH HHS P01 CA049605NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL129061NHLBI NIH HHS U10 HL069291NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069246NHLBI NIH HHS UG1 HL069249NHLBI NIH HHS UG1 HL069254NHLBI NIH HHS UG1 HL069278NHLBI NIH HHS UG1 HL069290NHLBI NIH HHS UG1 HL069291NHLBI NIH HHS UG1 HL069301
Abstract
Initial therapy of chronic graft-
Indexed as
PhotopheresisAgedCalcineurin InhibitorsChronic DiseaseDisease-Free SurvivalFemaleGraft vs Host DiseaseHumansMaleMiddle AgedPrednisoloneSirolimusSurvival RateCalcineurin InhibitorsPrednisoloneSirolimus
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.